Carcinoma, Renal Cell Clinical Trial
Official title:
PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status
Background:
- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor
tissue show up more clearly during scans. Researchers want to see how well it works for
scans for people who have kidney cancer.
Objectives:
- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney
cancer.
Eligibility:
- Adults at least 18 years of age with kidney cancer that will be treated with surgery.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected.
- Participants will have two positron emission tomography (PET) scans of their kidneys.
They will have the scans before and after receiving an injection of 18F-VM4-037. The
scans will take about 2 hours to complete.
- About 3 weeks after the PET scans, participants will provide tumor tissue samples from
their kidneys.
- This is a scanning study only. Treatment will not be provided as part of this study.
BACKGROUND:
- Carbonic Anhydrase IX (CA IX) is a hypoxia-inducible enzyme regulated by the Von Hippel
Lindau (VHL) protein that is commonly overexpressed in certain malignancies including
renal cell carcinoma (RCC) and may have prognostic significance.
- The VHL gene is commonly mutated or inactivated in RCC tumors and VHL activity
regulated the expression and activity of not only CAIX but also CAXII as well as other
genes critical for tumor angiogenesis such as vascular endothelial growth factor
(VEGF), glucose transporter 1 (GLUT1), glucose transporter 3 (GLUT 3) and platelet
derived growth factor (PDGF).
- 18F-VM4-037 is an imaging drug product formulation which binds to the active site
ligand of CA-IX and also binds to CAXII. We propose to evaluate 18F-VM4-037 as a
positron emission imaging (PET) radiopharmaceutical for the in vivo detection of CA-IX
and CAXII in renal tumors.
STUDY OBJECTIVES
PRIMARY OBJECTIVE:
- To evaluate the biodistribution of 18F-VM4-037 within tumor and non-tumor tissues.
- To assess safety of 18F-VM4-037 in patients with primary or metastatic RCC.
ELIGIBILITY:
- Subject is greater than or equal to 18 years old, Eastern Cooperative Oncology Group
(ECOG) 0-2.
- Subject must have confirmed primary RCC (greater than or equal to 2.5cm) in diameter on
conventional imaging modality or extrarenal/extrahepatic RCC lesion (greater than or
equal to 1cm).
DESIGN:
- Twenty subjects with primary RCC greater than or equal to 2.5cm in diameter or
extrarenal/extrahepatic lesion suspicious for metastatic RCC (greater than or equal to 1cm
in diameter) scheduled for clinically indicated surgery or biopsy will undergo dynamic
18F-VM4-037 PET/CT imaging. Results will be compared with pathology.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248389 -
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
|
Phase 1 | |
Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT00158782 -
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
|
Phase 1 | |
Completed |
NCT03109015 -
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
|
Phase 2 | |
Completed |
NCT00363194 -
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
|
Phase 1 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT00842790 -
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
|
N/A | |
Completed |
NCT00529802 -
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT00387764 -
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
Phase 3 | |
Completed |
NCT00356460 -
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00338884 -
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT00095186 -
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
Completed |
NCT00079612 -
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04489771 -
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
|
Phase 2 | |
Completed |
NCT00516672 -
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05104905 -
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT03111901 -
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 |